organ
transplant
essenti
effici
approach
replac
dysfunct
organ
patient
suffer
endstag
organ
diseas
howev
allogen
transplant
induc
seri
allograft
reject
episod
immun
respons
mainli
mediat
alloreact
cell
therefor
global
immunosuppress
agent
cyclosporin
csa
need
stop
acut
allograft
reject
suppress
cell
activ
hand
regulatori
cell
treg
play
critic
role
maintain
allograft
surviv
toler
inhibit
alloreact
cell
activ
reduct
gener
activ
contribut
allograft
reject
although
convent
immunosuppress
prevent
acut
reject
may
also
caus
sever
side
effect
includ
tumor
infect
furthermor
global
immunosuppress
agent
csa
inhibit
gener
function
treg
like
hinder
toler
induct
although
anoth
global
immunosuppress
rapamycin
typic
mtor
inhibitor
spare
treg
may
still
caus
side
effect
global
immunosuppress
agent
therefor
imper
seek
altern
immunosuppress
compromis
treg
yet
high
effici
suppress
low
toxic
high
afford
emodin
activ
anthraquinon
origin
isol
certain
natur
plant
includ
rheum
palmatum
cassia
obtusifolia
emodin
long
use
treat
chronic
kidney
diseas
side
effect
recent
mani
studi
also
document
lax
effect
emodin
well
inhibitori
effect
tumor
virus
bacteria
inflamm
without
major
side
effect
furthermor
emodin
also
avail
china
low
cost
therefor
emodin
may
exhibit
uniqu
advantag
mtor
inhibitor
term
side
effect
issu
afford
two
previou
public
demonstr
emodin
inhibit
acut
allograft
reject
liver
transplant
anim
model
nevertheless
cellular
molecular
mechan
underli
suppress
liver
allograft
reject
unknown
also
unclear
whether
emodin
suppress
reject
type
organ
transplant
beyond
liver
allograft
may
develop
spontan
toler
studi
found
emodin
significantli
prolong
surviv
skin
allograft
stringent
transplant
model
combin
treatment
emodin
csa
extend
skin
allograft
surviv
emodin
significantli
increas
frequenc
treg
reduc
number
effector
cell
furthermor
treg
isol
emodintr
recipi
mice
potent
suppress
allograft
reject
deriv
control
recipi
suggest
emodin
enhanc
treg
function
emodin
also
suppress
alloantibodi
product
hinder
dendrit
cell
dc
matur
posttransplant
final
demonstr
emodin
inhibit
cell
prolifer
vitro
block
mtor
signal
transduct
balbc
male
mice
week
old
male
obtain
guangdong
medic
laboratori
anim
center
guangdong
china
mice
background
purchas
jackson
laboratori
bar
harbor
usa
mice
hous
specif
pathogenfre
condit
experi
perform
accord
chines
nation
guidelin
care
use
laboratori
anim
approv
institut
anim
care
use
committe
guangdong
provinci
academi
chines
medic
scienc
ref
skin
donor
wildtyp
balbc
mice
male
skin
graft
recipi
mice
roundshap
fullthick
trunk
skin
approxim
size
transplant
dorsal
flank
area
recipi
mous
secur
bandag
bandaid
johnson
johnson
new
brunswick
nj
usa
bandag
remov
day
transplant
skin
allograft
reject
monitor
daili
defin
graft
necrosi
greater
describ
previou
public
mice
randomli
divid
control
group
group
treat
emodin
mgkg
bodi
weight
cyclosporin
csa
mgkg
bodi
weight
emodin
plu
csa
four
consecut
week
graft
rejectionsampl
collect
csa
emodin
sigma
prepar
salin
sodium
carboxymethyl
cellulos
cmcna
sigma
respect
control
group
receiv
cmcna
oral
primari
data
show
oral
administr
cmcna
alter
allograft
reject
compar
untreat
group
unpublish
observ
emodin
also
administ
oral
csa
given
intraperiton
inject
deplet
treg
recipi
mice
treat
ip
ab
clone
ebiosci
mg
day
ab
clone
ebiosci
mg
day
posttransplant
describ
previous
allograft
fix
paraformaldehyd
h
embed
paraffin
tissu
cut
thick
section
place
slide
section
use
h
e
immunohistochemistri
stain
immunohistochemistri
slide
section
incub
primari
antibodi
abcam
overnight
secondari
antibodi
hrpantirabbit
igg
maxim
follow
diaminobenzidin
color
develop
quantit
analys
slide
imag
magnif
area
inflammationinfiltr
integr
optic
densiti
iod
measur
use
imagepro
plu
softwar
drain
lymph
node
ln
spleen
cell
harvest
stain
clone
clone
clone
clone
clone
clone
clone
antibodi
clone
tmbeta
bd
bioscienc
determin
intracellular
express
cell
fix
permeat
accord
protocol
factor
fixationpermeabil
concentr
diluent
kit
ebiosci
cell
stain
antibodi
clone
ebiosci
final
analyz
flow
cytomet
facscalibur
bd
bioscienc
purifi
treg
adopt
transfer
experi
spleen
cell
stain
clone
clone
separ
clone
clone
tmbeta
ab
bd
bioscienc
cell
sort
facsaria
iii
bd
bioscienc
puriti
sort
cell
typic
recipi
mice
puls
intraperiton
mg
edu
ribobio
pb
day
transplant
h
later
spleen
ln
cell
isol
singlecel
suspens
prepar
edu
detect
use
stain
kit
ribobio
accord
manufactur
instruct
cell
stain
cell
surfac
marker
clone
clone
ab
clone
bd
bioscienc
detect
cell
apoptosi
cell
stain
surfac
marker
annexin
vfitc
accord
protocol
annexin
vfitc
apoptosi
detect
kit
bd
pharmingen
cell
final
analyz
via
flow
cytomet
facscalibur
facssort
cell
deriv
mice
cultur
irradi
balbc
spleen
cell
absenc
presenc
csa
emodin
plate
corn
costar
complet
rpmi
medium
fc
mm
glutamin
uml
penicillin
streptomycin
day
respect
cell
puls
thymidin
per
well
last
h
final
harvest
analyz
scintil
counter
perkin
elmer
wellesley
usa
spleen
cell
deriv
balbc
mice
harvest
red
blood
cell
lyse
b
cell
splenocyt
first
deplet
use
microbead
miltenyi
biotec
via
neg
select
cell
stain
dilut
serum
transplant
mice
incub
peantimous
igm
fitcantimous
igg
biolegend
mean
fluoresc
intens
determin
flow
cytomet
facscalibur
bd
bioscienc
cultur
cell
lyse
ripa
buffer
mm
tri
ph
mm
nacl
triton
mm
ethylenediaminetetraacet
acid
cell
protein
extract
use
ripa
buffer
protein
concentr
measur
use
bca
kit
pierc
il
usa
sampl
run
sdspage
gel
transfer
onto
pvdf
membran
tbst
milk
use
block
membran
incub
primari
antibodi
cell
signal
technolog
overnight
incub
membran
wash
incub
secondari
antibodi
hrpconjug
antirabbit
igg
abbkin
h
gapdh
cell
signal
technolog
also
use
load
control
final
signal
detect
ecl
method
promega
analyz
imag
j
program
softwar
comparison
mean
perform
use
student
ttest
oneway
anova
data
present
mean
sd
analyz
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
analysi
graft
surviv
conduct
use
method
logrank
test
valu
p
consid
statist
signific
studi
effect
emodin
allograft
reject
mice
receiv
skin
graft
donor
balbc
mous
treat
emodin
andor
csa
shown
figur
found
emodin
significantli
prolong
skin
allograft
surviv
compar
control
median
surviv
time
mst
vs
day
p
allograft
surviv
time
recipi
mice
treat
csa
also
longer
control
group
mst
vs
day
p
importantli
combin
treatment
emodin
csa
extend
skin
allograft
surviv
compar
treatment
either
csa
emodin
alon
mst
vs
day
p
sinc
emodin
suppress
allograft
reject
ask
whether
emodin
would
reduc
cellular
infiltr
allograft
graftinfiltr
cell
analyz
h
e
immunohistochem
stain
day
transplant
h
e
stain
show
obviou
cellular
infiltr
skin
allograft
recipi
without
treatment
much
less
cellular
infiltr
observ
recipi
treat
emodin
csa
figur
c
similarli
immunohistochemistri
reveal
obviou
decreas
cell
infiltr
skin
allograft
recipi
treat
emodin
andor
csa
compar
control
recipi
figur
data
suggest
emodin
inde
suppress
allograft
reject
amelior
alloreact
cell
infiltr
skin
allograft
determin
whether
emodin
would
control
effector
cell
teff
vivo
drain
ln
spleen
cell
emodin
csatreat
recipi
mice
isol
day
transplant
analyz
via
edustain
fac
analysi
repres
figur
emodin
csa
obvious
decreas
percentag
absolut
number
effector
cell
ln
spleen
recipi
furthermor
found
either
emodin
csa
alon
suppress
prolifer
cell
recipi
mice
emodin
plu
csa
inhibit
prolifer
compar
either
emodin
csa
alon
figur
control
isol
spleen
cell
mice
without
skin
transplant
observ
differ
cell
number
untreat
emodintr
group
data
shown
hand
emodin
promot
apoptosi
effector
cell
day
transplant
figur
also
demonstr
emodin
induc
apoptosi
total
cell
day
posttransplant
figur
supplementari
materi
thu
data
suggest
emodin
hinder
effector
cell
expansionprolifer
induc
cell
apoptosi
impli
treatment
dose
emodin
cytotox
regulatori
cell
play
import
role
longterm
transplant
surviv
toler
thu
examin
emodin
would
suppress
allograft
reject
induc
treg
drain
ln
spleen
cell
isol
day
allogen
skin
transplant
treg
enumer
flow
cytometri
shown
figur
emodin
significantli
increas
percentag
absolut
number
treg
drain
ln
csa
opposit
furthermor
reduct
ln
treg
number
result
csa
treatment
total
revers
recipi
treat
emodin
csa
figur
hand
markedli
varianc
frequenc
absolut
number
splenic
treg
group
similar
find
also
seen
day
skin
allotransplant
data
shown
data
suggest
emodin
promot
treg
gener
mainli
drain
ln
recipi
mice
previou
studi
demonstr
treg
potent
inhibit
cell
prolifer
transplant
reject
treg
henc
ask
whether
emodin
would
also
exert
suppress
effect
allograft
reject
induc
treg
measur
percentag
absolut
number
treg
ln
spleen
recipi
mice
via
flow
cytometri
day
allogen
skin
transplant
demonstr
emodin
csa
significantli
increas
percentag
treg
ln
spleen
recipi
figur
suggest
emodin
gener
promot
develop
treg
vivo
interestingli
emodin
increas
absolut
number
treg
ln
spleen
recipi
determin
whether
emodin
also
enhanc
suppress
function
treg
treg
isol
recipi
mice
treat
without
emodin
andor
csa
treg
transfer
lymphocytedefici
mice
receiv
syngen
cell
well
skin
allograft
shown
figur
adopt
transfer
convent
cell
recipi
caus
reject
skin
allograft
control
recipi
reject
allograft
transfer
control
treg
cell
extend
allograft
surviv
compar
cell
alon
howev
transfer
treg
deriv
emodintr
csatreat
recipi
mice
result
longer
allograft
surviv
control
treg
deriv
control
recipi
suggest
emodin
enhanc
suppress
function
treg
transfer
treg
deriv
csa
emodintr
recipi
also
caus
longer
allograft
surviv
treg
recipi
treat
csa
alon
hand
treg
deriv
recipi
mice
treat
either
emodin
csa
prolong
allograft
surviv
effect
control
treg
deriv
control
recipi
figur
indic
emodin
csa
alter
suppress
capac
treg
given
emodin
induc
treg
anim
model
ask
whether
effect
emodin
allograft
surviv
depend
treg
mice
receiv
skin
graft
balbc
mous
treat
emodin
csa
treg
recipi
deplet
use
ab
shown
figur
deplet
treg
larg
revers
skin
allograft
surviv
prolong
emodin
deplet
treg
partial
abrog
allograft
surviv
extend
emodin
contrast
deplet
either
treg
significantli
shorten
allograft
surviv
induc
csa
control
experi
isotyp
control
ab
alter
allograft
surviv
data
shown
result
suggest
treg
contribut
allograft
surviv
induc
emodin
given
antidonor
antibodi
play
role
allograft
reject
examin
whether
emodin
also
reduc
donorspecif
antibodi
measur
igg
igm
serum
mice
treat
csa
andor
emodin
via
fac
analys
use
balbc
splenocyt
target
cell
shown
figur
either
emodin
csa
significantli
lower
igg
igm
level
week
transplant
administr
csa
emodin
decreas
igg
igm
level
compar
treatment
csa
emodin
alon
data
indic
emodin
inde
inhibit
alloantibodi
product
determin
emodin
affect
dc
matur
posttransplant
drain
ln
spleen
cell
isol
day
allogen
skin
transplant
dc
enumer
flow
cytometri
shown
figur
treatment
either
csa
emodin
reduc
cell
number
ln
recipi
mice
howev
combin
treatment
csa
emodin
treatment
csa
emodin
alon
significantli
decreas
cell
number
spleen
mice
figur
hand
either
csa
emodin
reduc
cell
number
spleen
ln
recipi
figur
find
suggest
emodin
reduc
dc
number
ln
recipi
mice
decreas
dc
number
spleen
recipi
sinc
found
emodin
suppress
allograft
reject
cell
infiltr
allograft
examin
whether
emodin
would
also
inhibit
cell
prolifer
vitro
determin
effect
emodin
alloreact
cell
prolifer
vitro
oneway
mlr
set
use
irradi
balbc
splenocyt
stimul
cell
respond
shown
figur
either
emodin
csa
inhibit
cell
prolifer
figur
day
figur
mlr
cultur
moreov
combin
treatment
emodin
csa
suppress
cell
prolifer
compar
treatment
emodin
csa
alon
previou
experi
use
rapamycin
inhibitor
mtor
prove
mtor
signal
transduct
suppress
develop
function
treg
rapamycin
promot
treg
gener
sinc
result
demonstr
emodin
increas
frequenc
treg
determin
whether
emodin
would
also
induc
treg
block
mtor
signal
cell
activ
mlr
medium
without
emodin
h
phosphoryl
protein
measur
via
western
blot
shown
figur
emodin
effect
inhibit
phosphoryl
downstream
protein
compar
control
group
csa
slightli
reduc
phosphoryl
result
indic
emodin
like
exert
effect
treg
gener
cell
prolifer
block
mtor
signal
pathway
csa
wide
use
immunosuppress
agent
clinic
treat
autoimmun
diseas
transplant
reject
howev
addit
common
side
effect
csa
hinder
allograft
toler
dampen
treg
therefor
necessari
develop
new
therapeut
drug
suppress
allograft
reject
side
effect
particular
immunosuppress
agent
spare
treg
highli
prefer
use
mous
model
skin
transplant
analyz
efficaci
emodin
natur
molecul
extract
r
palmatum
suppress
transplant
reject
data
demonstr
emodin
suppress
cell
infiltr
allograft
prolong
allograft
surviv
administr
emodin
induc
treg
inhibit
expans
effector
cell
transplant
mice
emodin
also
suppress
alloantibodi
product
hinder
dc
matur
posttransplant
final
emodin
suppress
cell
prolifer
mtor
signal
vitro
thu
emodin
may
repres
newli
emerg
immunosuppress
could
util
clinic
transplant
result
demonstr
emodin
suppress
effector
cell
expans
promot
cell
apoptosi
recipi
mice
suggest
emodin
noncytotox
anim
model
howev
previou
studi
show
emodin
induc
apoptosi
dalton
lymphoma
cell
vivo
via
modul
hydrogen
peroxid
metabol
antioxid
enzym
although
unclear
emodin
induc
apoptosi
lymphoma
cell
primari
cell
specul
rapidli
grow
tumor
cell
may
vulner
mitochondri
pathway
apoptosi
normal
primari
cell
wildtyp
mice
treg
play
key
role
maintain
immun
homeostasi
toler
repres
small
fraction
cell
express
chain
receptor
either
induct
endogen
treg
adopt
transfer
exogen
treg
prevent
autoimmun
diseas
allograft
reject
anim
model
found
emodin
upregul
treg
drain
ln
transplant
mice
csa
reduc
number
suggest
emodin
csa
suppress
allograft
reject
via
total
differ
mechan
csa
common
immunosuppress
suppress
allograft
reject
format
complex
prevent
cell
activ
result
reduc
express
impair
gener
treg
compromis
toler
studi
csa
treatment
led
similar
reduct
frequenc
number
treg
revers
emodin
administr
suggest
emodin
correct
defici
csa
term
repress
treg
thu
potenti
tolerancebreak
effect
csa
may
offset
emodin
unclear
frequenc
number
treg
spleen
affect
emodin
possibl
increas
treg
drain
ln
recipi
mice
treat
emodin
due
presenc
alloantigenspecif
treg
given
agspecif
ttreg
cell
frequenc
gener
lower
spleen
drain
ln
hand
deplet
treg
mostli
revers
allograft
surviv
extend
emodin
indic
suppress
allograft
reject
emodin
mostli
depend
treg
recent
studi
shown
cell
also
treg
suppress
convent
cell
respons
autoimmun
diseas
previous
demonstr
cell
treg
also
potent
suppress
allograft
reject
convent
treg
studi
found
emodin
csa
significantli
increas
frequenc
treg
ln
spleen
recipi
indic
signal
pathway
activ
treg
differ
activ
treg
interestingli
emodin
augment
absolut
number
treg
ln
spleen
possibl
treg
induc
emodin
migrat
drain
ln
allograft
hand
neither
emodin
csa
enhanc
suppress
capac
treg
impli
emodininduc
treg
necessarili
alloantigenspecif
furthermor
deplet
treg
partial
revers
allograft
surviv
induc
emodin
indic
inhibit
allograft
reject
emodin
total
depend
treg
demonstr
emodin
induc
treg
inhibit
convent
cell
prolifer
well
accept
mtor
signal
import
regul
gener
treg
mtor
inhibitor
rapamycin
induc
treg
therefor
specul
emodin
exert
suppress
effect
cell
respons
via
inhibit
mtor
signal
lead
increas
treg
gener
inde
found
emodintr
cell
exhibit
dramat
decreas
activ
mtor
signal
induc
tcr
stimul
also
reduct
prolifer
indic
emodin
suppress
allograft
reject
block
tcell
mtor
signal
lead
treg
gener
turn
prolong
allograft
surviv
donorspecif
antibodi
alloantibodi
play
import
role
mediat
allograft
reject
found
emodin
suppress
product
igg
igm
alloantibodi
allotransplant
mechan
underli
suppress
alloantibodi
product
unknown
possibl
cell
help
b
cell
differenti
function
compromis
due
suppress
cell
activ
emodin
dendrit
cell
play
import
role
cell
activ
dc
recipi
facilit
allograft
reject
promot
expans
alloreact
cell
studi
found
emodin
reduc
dc
number
ln
recipi
mice
decreas
dc
number
spleen
recipi
suggest
emodin
hinder
dc
matur
context
allotransplant
remain
determin
emodin
differenti
impact
subset
dc
ln
spleen
recipi
mice
howev
result
actual
consist
previou
studi
show
emodin
inhibit
dc
matur
vitro
impli
emodin
inde
suppress
dc
differenti
matur
also
unclear
emodin
reduc
dc
number
possibl
emodin
regul
express
variou
tolllik
receptor
conclus
emodin
inhibit
alloimmun
respons
induc
treg
suppress
alloantibodi
product
hinder
dc
matur
block
mtor
signal
remain
defin
emodin
also
regul
gener
function
innat
immun
cell
includ
mdsc
macrophag
nk
cell
result
lay
groundwork
clinic
trial
use
emodin
effect
immunosuppress
suppress
allograft
reject
even
autoimmun
studi
carri
accord
recommend
chines
nation
guidelin
care
use
laboratori
anim
protocol
approv
institut
anim
care
use
committe
guangdong
provinci
academi
chines
medic
scienc
fq
design
perform
experi
hl
cll
conduct
partial
experi
gn
provid
idea
edit
manuscript
zd
design
experi
wrote
paper
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
